Top Sites>Plus Therapeutics (PSTV) - Home

Crawl-delay: 10

Sitemap: https://plustherapeutics.com/sitemap.xml
Sitemap: https://plustherapeutics.com/sitemap.rss

# START YOAST BLOCK
# ---------------------------
User-agent: *
Disallow:

Sitemap: https://plustherapeutics.com/sitemap_index.xml
# ---------------------------
# END YOAST BLOCK

Generated by All in One SEO v4.9.6.2, this is an llms.txt file, used by LLMs to index the site.

# Plus Therapeutics (PSTV)

Plus Therapeutics (PSTV)

## Sitemaps

- [XML Sitemap](https://plustherapeutics.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [StockTwits: Boardroom Exclusive with Dr. Marc Hedrick](https://plustherapeutics.com/stocktwits-boardroom-exclusive-with-dr-marc-hedrick/)
- [BioSpace: The Radiotherapeutics Moment - How Isotopes are Changing Cancer Treatment](https://plustherapeutics.com/biospace-the-radiotherapeutics-moment-how-isotopes-are-changing-cancer-treatment/)
- [Business of Biotech Podcast: Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.](https://plustherapeutics.com/business-of-biotech-podcast-radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d/)
- [Theranostics earmarked as “the future” of radiopharmaceuticals](https://plustherapeutics.com/theranostics-earmarked-as-the-future-of-radiopharmaceuticals/)
- [What emerging technologies or scientific breakthroughs do you believe will most reshape biopharma in the next 10 years?](https://plustherapeutics.com/what-emerging-technologies-or-scientific-breakthroughs-do-you-believe-will-most-reshape-biopharma-in-the-next-10-years/)
- [AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics](https://plustherapeutics.com/ai-powered-diagnostics-and-targeted-radiotherapy-for-cns-cancers-with-dr-marc-hedrick-plus-therapeutics/)
- [JPM 2026: what’s the outlook like this year?](https://plustherapeutics.com/jpm-2026-whats-the-outlook-like-this-year/)
- [Phase 1 RNL-186 Shows Promise in Leptomeningeal Metastases: Andrew Brenner, MD, PhD](https://plustherapeutics.com/phase-1-rnl-186-shows-promise-in-leptomeningeal-metastases-andrew-brenner-md-phd/)
- [Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers](https://plustherapeutics.com/plus-therapeutics-advancing-targeted-radiotherapeutics-for-rare-difficult-to-treat-cancers-2/)
- [Houston Business Journal](https://plustherapeutics.com/houston-business-journal/)
- [Progress, Potential, and Possibilities Show](https://plustherapeutics.com/progress-potential-and-possibilities-show/)
- [Stocktwits Interview with Plus Therapeutics CEO](https://plustherapeutics.com/stocktwits-interview-with-plus-therapeutics-ceo/)
- [Game on Glio Podcast with Dr. Toral Patel and Dr. Andrew Brenner](https://plustherapeutics.com/game-on-glio-podcast-with-dr-toral-patel-and-dr-andrew-brenner/)
- [Q&A: Metastatic cancer assay for ‘getting people answers’](https://plustherapeutics.com/qa-metastatic-cancer-assay-for-getting-people-answers/)
- [pharmaphorum podcast: On Targeted Radiotherapeutics](https://plustherapeutics.com/pharmaphorum-podcast-on-targeted-radiotherapeutics/)
- [Can Radiotherapeutics and Early Detection Offer a Breakthrough for Rare CNS Cancer?](https://plustherapeutics.com/can-radiotherapeutics-and-early-detection-offer-a-breakthrough-for-rare-cns-cancer/)
- [Radiopharma pipeline builds ahead of key data](https://plustherapeutics.com/radiopharma-pipeline-builds-ahead-of-key-data/)
- [CNSide® at BioHouston](https://plustherapeutics.com/cnside-at-biohouston/)
- [LiveLung Leptomeningeal Metastases Webinar](https://plustherapeutics.com/livelung-leptomeningeal-metastases-webinar/)
- [Breaking barriers in leptomeningeal metastases diagnosis with CNSide Diagnostics](https://plustherapeutics.com/breaking-barriers-in-leptomeningeal-metastases-diagnosis-with-cnside-diagnostics/)
- [Adding Up: Plus Therapeutics Gets First Metastatic CNS Cancer Assay Insured](https://plustherapeutics.com/adding-up-plus-therapeutics-gets-first-metastatic-cns-cancer-assay-insured/)
- [Houston cancer diagnostics company enters new phase with patient testing](https://plustherapeutics.com/houston-cancer-diagnostics-company-enters-new-phase-with-patient-testing/)
- [CLIA Accreditation Clears Path for CNSide Diagnostics’ CSF Assay Platform](https://plustherapeutics.com/clia-accreditation-clears-path-for-cnside-diagnostics-csf-assay-platform/)
- [KOL Symposium at SNO/ASCO CNS Metastases 2025](https://plustherapeutics.com/kol-symposium-at-sno-asco-cns-metastases-2025/)
- [KSAT News: ReSPECT-GBM at the Mays Cancer Center](https://plustherapeutics.com/ksat-news-respec-gbm-at-the-mays-cancer-center/)
- [Using Targeted Radiotherapies to Treat Challenging CNS Cancers](https://plustherapeutics.com/using-targeted-radiotherapies-to-treat-challenging-cns-cancers/)
- [What role is precision medicine playing in transforming cancer treatment — and how are developers adapting?](https://plustherapeutics.com/pharmas-almanac-interview/)
- [Central nervous system cancer metastases – the evolution of diagnostics and treatment](https://plustherapeutics.com/the-evolution-of-diagnostics-and-treatment/)
- [Medical Device Network Interview with CNSide® President](https://plustherapeutics.com/medical-device-network-interview-with-cnside-president/)
- [Fox SA Interview with Andrew Brenner, MD, PhD](https://plustherapeutics.com/fox-sa-interview-with-andrew-brenner-md/)
- [Cancer Network Interviews with Andrew Brenner, MD, PhD](https://plustherapeutics.com/cancer-network-interviews-with-andrew-brenner-md/)
- [Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers](https://plustherapeutics.com/plus-therapeutics-advancing-targeted-radiotherapeutics-for-rare-difficult-to-treat-cancers/)
- ["The Power of Plus Therapeutics" with Game on Glio](https://plustherapeutics.com/the-power-of-plus-therapeutics-with-game-on-glio/)
- [Targeting CNS Cancers with Precision Radiotherapeutics](https://plustherapeutics.com/targeting-cns-cancers-with-precision-radiotherapeutics/)
- [Plus Therapeutics CEO Interview with Alpha Street](https://plustherapeutics.com/plus-therapeutics-ceo-interview-with-alpha-street/)
- ["Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma"](https://plustherapeutics.com/rhenium-obisbemeda-improves-survival-in-recurrent-glioblastoma/)
- ["A New Way to Treat Brain Cancer?" by Andrew Brenner, MD, PhD](https://plustherapeutics.com/a-new-way-to-treat-brain-cancer-by-andrew-brenner-md-phd/)
- [Inside the Latest in Targeted Radiotherapeutics with Plus Therapeutics CEO Dr. Marc Hedrick](https://plustherapeutics.com/xtalks-life-science-podcast/)
- [Peer-Reviewed Nature Communications Article](https://plustherapeutics.com/peer-reviewed-nature-communications-article/)
- [Nano Cap Podcast](https://plustherapeutics.com/nano-cap-podcast/)
- [Glioblastoma Patient Summit Presentation by Andrew Brenner, MD, PhD](https://plustherapeutics.com/glioblastoma-patient-summit-presentation-by-andrew-brenner-md-phd/)
- [SNO Annual LM Symposium](https://plustherapeutics.com/sno-annual-lm-symposium/)
- [Interview with Scott Hamilton CARES Foundation](https://plustherapeutics.com/interview-with-scott-hamilton-cares-foundation/)
- [Glioblastoma Research Organization Interview with Marc Hedrick, M.D.](https://plustherapeutics.com/glioblastoma-research-organization-interview-with-marc-hedrick-m-d/)
- [SNO/ASCO CNS Metastases LM Symposium](https://plustherapeutics.com/sno-asco-cns-metastases-lm-symposium/)
- [Musella Foundation Patient Webinar on Recurrent Glioblastoma](https://plustherapeutics.com/musella-foundation-patient-webinar-on-recurrent-glioblastoma-2/)
- [JonesTrading Fireside Chat](https://plustherapeutics.com/jonestrading-fireside-chat/)
- [Plus Therapeutics at the Benzinga Virtual Healthcare Summit](https://plustherapeutics.com/28072-2/)
- [KOL Event: ReSPECT-GBM](https://plustherapeutics.com/kol-event-respect-gbm/)
- [Interview at the NYSE with IPO Edge](https://plustherapeutics.com/interview-at-the-nyse-with-ipo-edge/)
- [Key Opinion Leaders Roundtable](https://plustherapeutics.com/key-opinion-leaders-roundtable/)
- [Welcome to the Arena Interview with Plus Therapeutics](https://plustherapeutics.com/welcome-to-the-arena/)
- [Benzinga All Access Interview with Plus Therapeutics](https://plustherapeutics.com/plus-therapeutics-marc-hedrick-benzinga-all-access/)
- [Ongoing Research in Brain Tumor Therapies Provides Hope for the Future](https://plustherapeutics.com/targeted-oncology/)
- [Killing Cancer:  Meet This Innovative Biotech Player](https://plustherapeutics.com/killing-cancer/)
- [Musella Foundation Patient Webinar on Leptomeningeal Metastases](https://plustherapeutics.com/musella/)
- [Funding Granted:  Learn About The $17.6M CPRIT Research Grant](https://plustherapeutics.com/funding-granted/)

## Pages

- [Home](https://plustherapeutics.com/) - Plus Therapeutics is focused on developing innovative, targeted radiotherapeutics for adults & children with difficult-to-treat cancer. Leveraging novel drug formulations and technologies, our drugs are designed to deliver a single, safe and effective dose of radiation directly to the tumor
- [Contact](https://plustherapeutics.com/contact/)
- [Forward Looking Statement](https://plustherapeutics.com/forward/) - This information provided by PLUS THERAPEUTICS, Inc. (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be
- [REYOBIQ™ (rhenium Re186 obisbemeda)](https://plustherapeutics.com/reyobiq/)
- [Recurrent Glioblastoma](https://plustherapeutics.com/recurrent-glioblastoma/)
- [Careers](https://plustherapeutics.com/careers/)
- [Our Team](https://plustherapeutics.com/our-team/)
- [For Patients](https://plustherapeutics.com/for-patients/)
- [About Us](https://plustherapeutics.com/about-us/)
- [Pediatric Brain Cancer](https://plustherapeutics.com/pediatric-brain-cancer/)
- [Leptomeningeal Metastases](https://plustherapeutics.com/leptomeningeal-metastases/)
- [Partnership Opportunities](https://plustherapeutics.com/partnership-opportunities/)
- [Pipeline](https://plustherapeutics.com/pipeline/)
- [About Radiotherapeutics](https://plustherapeutics.com/about-radiotherapeutics/)
- [Social Media Guidelines](https://plustherapeutics.com/social/) - Welcome to PLUS THERAPEUTICS’ guidelines for social media sites, which may include Facebook, Instagram, LinkedIn, StockTwits, Twitter, Yahoo, Reddit, Threads and YouTube pages. We have created these social media platforms to support a community where employees, patients, researchers, health providers, and investors in PLUS THERAPEUTICS can stay up to date on company activities. PLUS THERAPEUTICS
- [Our Platform](https://plustherapeutics.com/our-platform/)
- [188RNL-BAM](https://plustherapeutics.com/188rnl-bam/)
- [Metastatic Colorectal Cancer](https://plustherapeutics.com/metastatic-colorectal-cancer/)
- [Hepatocellular Carcinoma](https://plustherapeutics.com/hepatocellular-carcinoma/)
- [Privacy Policy](https://plustherapeutics.com/privacy/) - Commitment to Data Privacy Protection Protecting the security and privacy of your personal data is important to PLUS THERAPEUTICS; therefore, we conduct our business in compliance with applicable laws on data privacy protection and data security. The policy below is designed to help you understand what data PLUS THERAPEUTICS may collect, how PLUS THERAPEUTICS uses
- [Terms of Use](https://plustherapeutics.com/tou/) - 1. Scope Any use of this web site provided by PLUS THERAPEUTICS, Inc. and/or its affiliates (“PLUS”), “PLUS Web Site”, is subject to these Terms of Use. You should carefully read the Terms of Use before using the PLUS Web Site. These Terms of Use may be amended, modified or replaced by other terms and

## Team

- [Russ Havranek](https://plustherapeutics.com/?team=russ-havranek) - Russ Havranek is the Executive Vice President of Commercial and Corporate Strategy. He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics. Mr. Havranek has over 28 years of leadership experience developing and commercializing diagnostic and therapeutic products at global, publicly traded, biopharma and medical device companies. His prior roles in
- [Randy H. Goodman](https://plustherapeutics.com/?team=randy-h-goodman) - Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutical, diagnostics, and medical device sectors. He has led the development of payer engagement strategies, health technology assessment (HTA) dossiers,
- [Andrew Sims](https://plustherapeutics.com/?team=andrew-sims) - Andrew Sims is Vice President and Chief Financial Officer at Plus Therapeutics, Inc. Mr. Sims arrived at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims
- [Colby Suire](https://plustherapeutics.com/?team=colby-suire) - Dr. Colby Suire serves as Vice President of Research & Development at CNSide Diagnostics and Plus Therapeutics, where he leads scientific strategy and execution to advance the CNSide™ platform and strengthen the Company’s translational and diagnostic capabilities. Colby is responsible for expanding CNSide’s assay portfolio across high-value oncology indications, including implementation of FISH and next-generation
- [Eric J. Daniels](https://plustherapeutics.com/?team=eric-j-daniels) - Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. Prior to joining Plus Therapeutics as the Chief Development Officer, from October 2021 through April 2026, Dr. Daniels served as the chief development officer of Kiora Pharmaceuticals (NASDAQ:KPRX). In addition, from
- [Ron Andrews](https://plustherapeutics.com/?team=ron-andrews) - Mr. Andrews currently is an experienced leader in the Diagnostics and Molecular Diagnostics industry with over 35 years leading various sized organizations from divisions of large global entities such as Abbott Diagnostics, Roche Molecular Diagnostics and LifeTechnologies/Thermo Fisher to public CEO roles in successful start-up organizations like Clarient Inc. (NASDAQ: CLRT) and Oncocyte Inc. (NASDAQ:
- [Daniel Ortega](https://plustherapeutics.com/?team=daniel-ortega) - Daniel Ortega is Vice President of Development and Technical Operations at Plus Therapeutics, Inc. He is responsible for end-to-end drug development, GMP manufacturing, clinical supply chain management, and CMC oversight across the company’s radiotherapeutic portfolio. Mr. Ortega brings nearly 20 years of pharmaceutical industry experience, including technical and leadership roles at Azaya Therapeutics, Mission Pharmacal,
- [Marc Hedrick](https://plustherapeutics.com/?team=marc-hedrick) - Dr. Marc Hedrick is the President and CEO at Plus Therapeutics, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery
- [Russell Bradley](https://plustherapeutics.com/?team=russell-bradley) - Mr. Bradley is currently President and General Manager, CNSide Diagnostics, LLC. Previously, Mr. Bradley led the Hematology Business Unit at Abbott Laboratories (NYSE: ABT) as General Manager. Before joining Abbott Labs, Mr. Bradley served as Senior Vice President of Corporate Development and Chief Marketing and Sales Officer of Luminex, Inc. (NASDAQ: LMNX – acquired by
- [Kyle Guse](https://plustherapeutics.com/?team=kyle-guse) - Kyle Guse, J.D., M.B.A., is an executive with 30 years of professional experience leading the world’s most innovative companies. For over a decade he served as Chief Financial Officer, General Counsel and Secretary of Atossa Therapeutics, Inc., a NASDAQ-listed company developing a drug to prevent and treat breast cancer, which had previously developed and marketed
- [Vladimir P. Torchilin](https://plustherapeutics.com/?team=vladimir-p-torchilin) - Dr. Torchilin is a University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. He obtained a M.S. in Chemistry as well as a Ph.D. and D.Sc. in Polymer Chemistry and Chemistry of Physiologically Active Compounds from Moscow University. In 1991, Dr. Torchilin joined MGH/Harvard Medical School as the Head of
- [An van Es-Johansson](https://plustherapeutics.com/?team=an-van-es-johansson) - An van Es-Johansson joined our Board in January 2020. Dr. van Es-Johansson currently serves as a Senior Advisor for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance. From 2005-2018, Dr. van Es-Johansson served in a range of executive roles
- [John McKew](https://plustherapeutics.com/?team=john-mckew) - Dr. McKew has 27 years of experience developing novel therapeutics where he successfully advanced therapies through preclinical and into clinical development. He is currently Chief Operating Officer of Lumos Pharma. Prior to Lumos Pharma, Dr. McKew was Vice President of Research at aTyr Pharma where he led a research team discovering and advancing protein-based therapeutics
- [Andrew Brenner](https://plustherapeutics.com/?team=andrew-brenner) - Dr. Brenner is a medical oncologist and tumor biologist with a focus in drug development for the management of primary brain tumors and breast neoplasms. His interests are in developing novel therapeutics for the treatment of malignancy with a focus on overcoming resistance to conventional therapeutics. This experience includes navigation of regulatory processes including IND
- [Michael Vogelbaum](https://plustherapeutics.com/?team=michael-vogelbaum) - Dr. Vogelbaum is an internationally known leader in neurosurgical oncology and distinguished investigator in laboratory research, translational and clinical trials in gliomas. He is currently Chief of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center. Dr. Vogelbaum is also the inventor of patented medical devices for delivering therapeutics directly to
- [Alireza Mohammadi](https://plustherapeutics.com/?team=alireza-mohammadi) - Dr. Mohammadi is a board-certified neurosurgeon who specializes in neurosurgical oncology including surgery and laser ablation of brain tumors as well as radiosurgery for brain and spine. He is currently practicing at the Neurosurgery Department and the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at the Cleveland Clinic. Since 2014, Dr. Mohammadi has also
- [Russell Lonser](https://plustherapeutics.com/?team=russell-lonser) - Dr. Lonser is a professor and chair of the Department of Neurological Surgery at The Ohio State University Wexner Medical Center, and currently holds the Dardinger Family Chair in Neurosurgical Oncology. Previously, he was chief of the Surgical Neurology Branch at the National Institutes of Health. Dr. Lonser specializes in the resection of brain, spinal
- [Nicholas Butowski](https://plustherapeutics.com/?team=nicholas-butowski) - Dr. Butowski is a neuro-oncologist who specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and a co-investigator of National Cancer Institute-supported North American Brain Tumor Consortium clinical trials. Dr. Butowski earned his medical degree at the University of Illinois at
- [Manish Aghi](https://plustherapeutics.com/?team=manish-aghi) - Dr. Manish Aghi is a neurosurgeon, scientist and current faculty member in the department of neurological surgery and graduate division of biomedical sciences, as well as a principal investigator in the Brain Tumor Research Center at UCSF. He completed his MD-PhD Program through the Medical Scientist Training Program at Harvard Medical School, followed by neurological
- [Howard Clowes](https://plustherapeutics.com/?team=howard-clowes) - Howard Clowes joined our Board in March 2020. A retired partner after nearly four decades at DLA Piper, a leading law firm, Mr. Clowes has served in leadership positions in the firm’s Corporate and Securities Practice, advising public and private companies on securities law, financing, Mergers and Acquisition and general corporate matters. At the law
- [Robert Lenk](https://plustherapeutics.com/?team=robert-lenk) - Robert Lenk joined our Board in March 2020. Dr. Lenk has over 35 years as pharmaceutical executive with deep expertise in nanoparticle drug development and drug formulation. He is currently President of Lenk Pharmaceuticals, a pharmaceuticals development consultant to multinational corporations and startups. Previously, Dr. Lenk has been Chief Scientific Officer of MediVector, Inc., President
- [Richard Hawkins](https://plustherapeutics.com/?team=richard-hawkins) - Richard J. Hawkins joined us as Director in December 2007 and was appointed to serve as Chairman in January 2018. Mr. Hawkins is currently the CEO of Lumos Pharma, Inc., a start-up pharma company. Mr. Hawkins founded LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems, and served Chairman and

## Categories

- [Uncategorized](https://plustherapeutics.com/category/uncategorized/)
- [Recent News](https://plustherapeutics.com/category/recent-news/)
- [Medical & Scientific Events](https://plustherapeutics.com/category/medical-scientific-events/)
- [Investor Events](https://plustherapeutics.com/category/investor-events/)

## Department

- [Management](https://plustherapeutics.com/department/management/)
- [Board of Directors](https://plustherapeutics.com/department/board-of-directors/)
- [Clinical Advisory Board](https://plustherapeutics.com/department/clinical-advisory-board/)
- [Scientific Advisory Board](https://plustherapeutics.com/department/scientific-advisory-board/)